Abstract
The optimal therapeutic intervention of pathologic N2 (pN2) non-small cell lung cancer (NSCLC) is still controversial. The argument and the debate about the selection of patients for multimodality therapy, the role of surgery, the choice of neoadjuvant treatment and sequential therapies have continued for years.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
